PMC:7386875 / 0-1313 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":780,"end":797},"obj":"Body_part"},{"id":"T2","span":{"begin":792,"end":797},"obj":"Body_part"},{"id":"T3","span":{"begin":869,"end":885},"obj":"Body_part"},{"id":"T4","span":{"begin":881,"end":885},"obj":"Body_part"},{"id":"T5","span":{"begin":1015,"end":1023},"obj":"Body_part"},{"id":"T6","span":{"begin":1029,"end":1038},"obj":"Body_part"},{"id":"T7","span":{"begin":1207,"end":1211},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma66772"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma66772"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma62851"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma50723"}],"text":"The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications\n\nAbstract\nThe recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the ensuing global pandemic has presented a health emergency of unprecedented magnitude. Recent clinical data has highlighted that coronavirus disease 2019 (COVID-19) is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke. Importantly, thrombotic complications are markers of severe COVID-19 and are associated with multiorgan failure and increased mortality. The evidence to date supports the concept that the thrombotic manifestations of severe COVID-19 are due to the ability of SARS-CoV-2 to invade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on the endothelial cell surface. However, in patients with COVID-19 the subsequent endothelial inflammation, complement activation, thrombin generation, platelet, and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, ultimately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measur"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":1202,"end":1211},"obj":"Body_part"},{"id":"T2","span":{"begin":1207,"end":1211},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0035552"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0001638"}],"text":"The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications\n\nAbstract\nThe recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the ensuing global pandemic has presented a health emergency of unprecedented magnitude. Recent clinical data has highlighted that coronavirus disease 2019 (COVID-19) is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke. Importantly, thrombotic complications are markers of severe COVID-19 and are associated with multiorgan failure and increased mortality. The evidence to date supports the concept that the thrombotic manifestations of severe COVID-19 are due to the ability of SARS-CoV-2 to invade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on the endothelial cell surface. However, in patients with COVID-19 the subsequent endothelial inflammation, complement activation, thrombin generation, platelet, and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, ultimately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measur"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":30,"end":40},"obj":"Disease"},{"id":"T2","span":{"begin":44,"end":52},"obj":"Disease"},{"id":"T3","span":{"begin":120,"end":167},"obj":"Disease"},{"id":"T4","span":{"begin":120,"end":153},"obj":"Disease"},{"id":"T5","span":{"begin":169,"end":177},"obj":"Disease"},{"id":"T6","span":{"begin":316,"end":340},"obj":"Disease"},{"id":"T7","span":{"begin":342,"end":350},"obj":"Disease"},{"id":"T8","span":{"begin":445,"end":455},"obj":"Disease"},{"id":"T9","span":{"begin":457,"end":478},"obj":"Disease"},{"id":"T10","span":{"begin":492,"end":498},"obj":"Disease"},{"id":"T12","span":{"begin":560,"end":568},"obj":"Disease"},{"id":"T13","span":{"begin":593,"end":611},"obj":"Disease"},{"id":"T14","span":{"begin":724,"end":732},"obj":"Disease"},{"id":"T15","span":{"begin":759,"end":767},"obj":"Disease"},{"id":"T16","span":{"begin":921,"end":929},"obj":"Disease"},{"id":"T17","span":{"begin":957,"end":969},"obj":"Disease"},{"id":"T18","span":{"begin":1212,"end":1222},"obj":"Disease"},{"id":"T19","span":{"begin":1224,"end":1242},"obj":"Disease"},{"id":"T20","span":{"begin":1248,"end":1254},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005399"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005098"},{"id":"A11","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0043726"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005279"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0005098"},{"id":"A21","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"}],"text":"The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications\n\nAbstract\nThe recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the ensuing global pandemic has presented a health emergency of unprecedented magnitude. Recent clinical data has highlighted that coronavirus disease 2019 (COVID-19) is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke. Importantly, thrombotic complications are markers of severe COVID-19 and are associated with multiorgan failure and increased mortality. The evidence to date supports the concept that the thrombotic manifestations of severe COVID-19 are due to the ability of SARS-CoV-2 to invade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on the endothelial cell surface. However, in patients with COVID-19 the subsequent endothelial inflammation, complement activation, thrombin generation, platelet, and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, ultimately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measur"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":213,"end":216},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T2","span":{"begin":227,"end":228},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":295,"end":298},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T4","span":{"begin":371,"end":372},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":780,"end":797},"obj":"http://purl.obolibrary.org/obo/CL_0000115"},{"id":"T6","span":{"begin":869,"end":885},"obj":"http://purl.obolibrary.org/obo/CL_0000115"},{"id":"T7","span":{"begin":982,"end":992},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T8","span":{"begin":1207,"end":1211},"obj":"http://purl.obolibrary.org/obo/UBERON_0001638"},{"id":"T9","span":{"begin":1207,"end":1211},"obj":"http://www.ebi.ac.uk/efo/EFO_0000816"},{"id":"T10","span":{"begin":1273,"end":1283},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications\n\nAbstract\nThe recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the ensuing global pandemic has presented a health emergency of unprecedented magnitude. Recent clinical data has highlighted that coronavirus disease 2019 (COVID-19) is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke. Importantly, thrombotic complications are markers of severe COVID-19 and are associated with multiorgan failure and increased mortality. The evidence to date supports the concept that the thrombotic manifestations of severe COVID-19 are due to the ability of SARS-CoV-2 to invade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on the endothelial cell surface. However, in patients with COVID-19 the subsequent endothelial inflammation, complement activation, thrombin generation, platelet, and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, ultimately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measur"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":809,"end":820},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"}],"text":"The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications\n\nAbstract\nThe recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the ensuing global pandemic has presented a health emergency of unprecedented magnitude. Recent clinical data has highlighted that coronavirus disease 2019 (COVID-19) is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke. Importantly, thrombotic complications are markers of severe COVID-19 and are associated with multiorgan failure and increased mortality. The evidence to date supports the concept that the thrombotic manifestations of severe COVID-19 are due to the ability of SARS-CoV-2 to invade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on the endothelial cell surface. However, in patients with COVID-19 the subsequent endothelial inflammation, complement activation, thrombin generation, platelet, and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, ultimately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measur"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":464,"end":486},"obj":"Phenotype"},{"id":"T2","span":{"begin":492,"end":498},"obj":"Phenotype"},{"id":"T3","span":{"begin":1202,"end":1222},"obj":"Phenotype"},{"id":"T4","span":{"begin":1224,"end":1242},"obj":"Phenotype"},{"id":"T5","span":{"begin":1248,"end":1254},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001907"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0001297"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002625"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0002204"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0001297"}],"text":"The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications\n\nAbstract\nThe recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the ensuing global pandemic has presented a health emergency of unprecedented magnitude. Recent clinical data has highlighted that coronavirus disease 2019 (COVID-19) is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke. Importantly, thrombotic complications are markers of severe COVID-19 and are associated with multiorgan failure and increased mortality. The evidence to date supports the concept that the thrombotic manifestations of severe COVID-19 are due to the ability of SARS-CoV-2 to invade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on the endothelial cell surface. However, in patients with COVID-19 the subsequent endothelial inflammation, complement activation, thrombin generation, platelet, and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, ultimately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measur"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":957,"end":969},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T2","span":{"begin":971,"end":992},"obj":"http://purl.obolibrary.org/obo/GO_0006956"},{"id":"T3","span":{"begin":1085,"end":1110},"obj":"http://purl.obolibrary.org/obo/GO_0002250"},{"id":"T4","span":{"begin":1273,"end":1298},"obj":"http://purl.obolibrary.org/obo/GO_0050820"},{"id":"T5","span":{"begin":1287,"end":1298},"obj":"http://purl.obolibrary.org/obo/GO_0050817"}],"text":"The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications\n\nAbstract\nThe recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the ensuing global pandemic has presented a health emergency of unprecedented magnitude. Recent clinical data has highlighted that coronavirus disease 2019 (COVID-19) is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke. Importantly, thrombotic complications are markers of severe COVID-19 and are associated with multiorgan failure and increased mortality. The evidence to date supports the concept that the thrombotic manifestations of severe COVID-19 are due to the ability of SARS-CoV-2 to invade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on the endothelial cell surface. However, in patients with COVID-19 the subsequent endothelial inflammation, complement activation, thrombin generation, platelet, and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, ultimately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measur"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":85},"obj":"Sentence"},{"id":"T2","span":{"begin":87,"end":95},"obj":"Sentence"},{"id":"T3","span":{"begin":96,"end":273},"obj":"Sentence"},{"id":"T4","span":{"begin":274,"end":499},"obj":"Sentence"},{"id":"T5","span":{"begin":500,"end":636},"obj":"Sentence"},{"id":"T6","span":{"begin":637,"end":894},"obj":"Sentence"},{"id":"T7","span":{"begin":895,"end":1255},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications\n\nAbstract\nThe recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the ensuing global pandemic has presented a health emergency of unprecedented magnitude. Recent clinical data has highlighted that coronavirus disease 2019 (COVID-19) is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke. Importantly, thrombotic complications are markers of severe COVID-19 and are associated with multiorgan failure and increased mortality. The evidence to date supports the concept that the thrombotic manifestations of severe COVID-19 are due to the ability of SARS-CoV-2 to invade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on the endothelial cell surface. However, in patients with COVID-19 the subsequent endothelial inflammation, complement activation, thrombin generation, platelet, and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, ultimately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measur"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2","span":{"begin":30,"end":40},"obj":"Disease"},{"id":"3","span":{"begin":44,"end":52},"obj":"Disease"},{"id":"48","span":{"begin":802,"end":807},"obj":"Gene"},{"id":"49","span":{"begin":809,"end":840},"obj":"Gene"},{"id":"50","span":{"begin":994,"end":1002},"obj":"Gene"},{"id":"51","span":{"begin":120,"end":167},"obj":"Species"},{"id":"52","span":{"begin":169,"end":179},"obj":"Species"},{"id":"53","span":{"begin":759,"end":769},"obj":"Species"},{"id":"54","span":{"begin":907,"end":915},"obj":"Species"},{"id":"60","span":{"begin":316,"end":340},"obj":"Disease"},{"id":"61","span":{"begin":342,"end":350},"obj":"Disease"},{"id":"62","span":{"begin":393,"end":417},"obj":"Disease"},{"id":"63","span":{"begin":445,"end":455},"obj":"Disease"},{"id":"64","span":{"begin":457,"end":486},"obj":"Disease"},{"id":"65","span":{"begin":492,"end":498},"obj":"Disease"},{"id":"66","span":{"begin":513,"end":537},"obj":"Disease"},{"id":"67","span":{"begin":560,"end":568},"obj":"Disease"},{"id":"68","span":{"begin":593,"end":611},"obj":"Disease"},{"id":"69","span":{"begin":626,"end":635},"obj":"Disease"},{"id":"70","span":{"begin":688,"end":698},"obj":"Disease"},{"id":"71","span":{"begin":724,"end":732},"obj":"Disease"},{"id":"72","span":{"begin":921,"end":929},"obj":"Disease"},{"id":"73","span":{"begin":957,"end":969},"obj":"Disease"},{"id":"74","span":{"begin":1124,"end":1140},"obj":"Disease"},{"id":"75","span":{"begin":1168,"end":1192},"obj":"Disease"},{"id":"76","span":{"begin":1202,"end":1222},"obj":"Disease"},{"id":"77","span":{"begin":1224,"end":1242},"obj":"Disease"},{"id":"78","span":{"begin":1248,"end":1254},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"tao:has_database_id","subj":"2","obj":"MESH:D013927"},{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:C000657245"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Gene:59272"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Gene:59272"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Gene:2147"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Tax:2697049"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:2697049"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Tax:2697049"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Tax:9606"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"MESH:C000657245"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:C000657245"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:D013927"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"MESH:D013927"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"MESH:D054556"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D020521"},{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"MESH:D013927"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:C000657245"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:D009102"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"MESH:D003643"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:D013927"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:C000657245"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"MESH:C000657245"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"MESH:D007249"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"MESH:D013927"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"MESH:D020246"},{"id":"A77","pred":"tao:has_database_id","subj":"77","obj":"MESH:D011655"},{"id":"A78","pred":"tao:has_database_id","subj":"78","obj":"MESH:D020521"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications\n\nAbstract\nThe recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the ensuing global pandemic has presented a health emergency of unprecedented magnitude. Recent clinical data has highlighted that coronavirus disease 2019 (COVID-19) is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke. Importantly, thrombotic complications are markers of severe COVID-19 and are associated with multiorgan failure and increased mortality. The evidence to date supports the concept that the thrombotic manifestations of severe COVID-19 are due to the ability of SARS-CoV-2 to invade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on the endothelial cell surface. However, in patients with COVID-19 the subsequent endothelial inflammation, complement activation, thrombin generation, platelet, and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, ultimately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measur"}